NO20062674L - Optimalisert uttrykking av HPV58-L1 i gjaer - Google Patents
Optimalisert uttrykking av HPV58-L1 i gjaerInfo
- Publication number
- NO20062674L NO20062674L NO20062674A NO20062674A NO20062674L NO 20062674 L NO20062674 L NO 20062674L NO 20062674 A NO20062674 A NO 20062674A NO 20062674 A NO20062674 A NO 20062674A NO 20062674 L NO20062674 L NO 20062674L
- Authority
- NO
- Norway
- Prior art keywords
- hpv58
- protein
- vlps
- vaccines
- prepare
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
- C07K14/01—DNA viruses
- C07K14/025—Papovaviridae, e.g. papillomavirus, polyomavirus, SV40, BK virus, JC virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
- A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/80—Vectors or expression systems specially adapted for eukaryotic hosts for fungi
- C12N15/81—Vectors or expression systems specially adapted for eukaryotic hosts for fungi for yeasts
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20023—Virus like particles [VLP]
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/20011—Papillomaviridae
- C12N2710/20034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2800/00—Nucleic acids vectors
- C12N2800/22—Vectors comprising a coding region that has been codon optimised for expression in a respective host
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Virology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Wood Science & Technology (AREA)
- Biochemistry (AREA)
- Zoology (AREA)
- Biotechnology (AREA)
- Veterinary Medicine (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Animal Behavior & Ethology (AREA)
- General Engineering & Computer Science (AREA)
- Microbiology (AREA)
- Biophysics (AREA)
- Gastroenterology & Hepatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Mycology (AREA)
- Epidemiology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US51921103P | 2003-11-12 | 2003-11-12 | |
PCT/US2004/037372 WO2005047315A2 (en) | 2003-11-12 | 2004-11-10 | Optimized expression of hpv 58 l1 in yeast |
Publications (2)
Publication Number | Publication Date |
---|---|
NO20062674L true NO20062674L (no) | 2006-06-09 |
NO340633B1 NO340633B1 (no) | 2017-05-15 |
Family
ID=34590374
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO20062674A NO340633B1 (no) | 2003-11-12 | 2006-06-09 | Nukleinsyremolekyl som omfatter en sekvens av nukleotider som koder for et HPV58-L1-protein, vektorer og vertsceller, fremgangsmåte for fremstilling av HPV58 L1 virusliknende partikler (VLP-er), samt fremgangsmåte for fremstilling av en vaksine for behandling eller forebygging av HPV infeksjoner. |
NO2017058C NO2017058I1 (no) | 2003-11-12 | 2017-11-10 | HPV 58 L1 protein |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NO2017058C NO2017058I1 (no) | 2003-11-12 | 2017-11-10 | HPV 58 L1 protein |
Country Status (32)
Country | Link |
---|---|
US (2) | US7498036B2 (no) |
EP (1) | EP1687329B8 (no) |
JP (2) | JP4912885B2 (no) |
KR (1) | KR101170654B1 (no) |
CN (1) | CN1942583B (no) |
AR (1) | AR046835A1 (no) |
AT (1) | ATE452977T1 (no) |
AU (1) | AU2004290032B2 (no) |
BE (1) | BE2015C070I2 (no) |
BR (1) | BRPI0416393B1 (no) |
CA (1) | CA2543928C (no) |
CY (2) | CY1113875T1 (no) |
DE (1) | DE602004024821D1 (no) |
DK (1) | DK1687329T3 (no) |
ES (1) | ES2340287T3 (no) |
FR (1) | FR15C0081I2 (no) |
HU (1) | HUS1500064I1 (no) |
IL (1) | IL175353A (no) |
IS (1) | IS2741B (no) |
LT (1) | LTC1687329I2 (no) |
LU (1) | LU92901I2 (no) |
MY (1) | MY139500A (no) |
NL (1) | NL300775I2 (no) |
NO (2) | NO340633B1 (no) |
NZ (1) | NZ546697A (no) |
PL (1) | PL1687329T3 (no) |
PT (1) | PT1687329E (no) |
RU (1) | RU2370538C2 (no) |
SI (1) | SI1687329T1 (no) |
TW (1) | TWI332988B (no) |
WO (1) | WO2005047315A2 (no) |
ZA (1) | ZA200603106B (no) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7858098B2 (en) * | 2002-12-20 | 2010-12-28 | Glaxosmithkline Biologicals, S.A. | Vaccine |
US8206950B2 (en) | 2003-06-09 | 2012-06-26 | Animal Technology Institute Taiwan | Fusion antigen used as vaccine and method of making them |
EP1730175B1 (en) * | 2004-03-24 | 2010-04-28 | Merck Sharp & Dohme Corp. | Optimized expression of hpv 52 l1 in yeast |
US20070243587A1 (en) * | 2006-04-14 | 2007-10-18 | Healthbanks Biotech Co., Ltd. | Using a reverse genetic engineering platform to produce protein vaccines and protein vaccine of avian influenza virus |
CN101148661B (zh) * | 2006-09-18 | 2013-01-02 | 中国医学科学院基础医学研究所 | 人乳头瘤病毒16型外壳蛋白病毒样颗粒及其制备方法和用途 |
EP2129394B1 (en) * | 2007-03-09 | 2012-06-20 | Merck Sharp & Dohme Corp. | Papillomavirus vaccine compositions |
US9364529B2 (en) | 2007-04-29 | 2016-06-14 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of human papillomavirus type 18 |
US9428555B2 (en) | 2007-04-29 | 2016-08-30 | Beijing Wantai Biological Pharmacy Enterprise Co., Ltd. | Truncated L1 protein of Human Papillomavirus type 16 |
EP2154149B1 (en) * | 2007-05-29 | 2019-07-10 | Xiamen University | A truncated l1 protein of human papillomavirus 6 |
CN101113417B (zh) * | 2007-06-22 | 2011-04-27 | 山东大学 | Hpv基因酵母体外翻译系统的建立 |
CN101200696B (zh) * | 2007-11-14 | 2011-07-20 | 山东大学 | 人乳头瘤病毒的酵母增殖模型及建立方法与应用 |
EP2223933B1 (en) * | 2007-11-23 | 2016-01-27 | Shanghai Zerun Biotechnology Co., Ltd. | Genes encoding major capsid protein l1 of human papilloma viruses |
KR20090073987A (ko) * | 2007-12-31 | 2009-07-03 | 정운원 | 인간유두종바이러스 유전자형 검사를 위한 프라이머, 프로브 및 이를 포함하는 dna칩, 이의 검사 방법 및 검사 키트 |
CN106377767A (zh) * | 2008-05-26 | 2017-02-08 | 卡迪拉保健有限公司 | 麻疹‑人乳头瘤组合疫苗 |
US9335868B2 (en) * | 2008-07-31 | 2016-05-10 | Apple Inc. | Capacitive sensor behind black mask |
AU2011258501B2 (en) | 2010-05-25 | 2016-07-07 | Qiagen Gaithersburg, Inc. | Fast results hybrid capture assay and associated strategically-truncated probes |
CN101857870B (zh) * | 2010-06-12 | 2012-09-05 | 上海泽润生物科技有限公司 | Hpv58 l1基因及载体、菌株和表达方法 |
CN102336822B (zh) * | 2010-07-16 | 2015-10-14 | 厦门大学 | 截短的人乳头瘤病毒58型l1蛋白 |
CN102154325B (zh) * | 2011-01-01 | 2013-08-21 | 上海生物制品研究所有限责任公司 | 针对人乳头瘤状病毒的疫苗及其制法和用途 |
BR112013032338B1 (pt) * | 2011-06-15 | 2021-04-20 | Posvax Co., Ltd | método para melhorar o rendimento de produção para proteína l1 do papilomavírus humano |
CN108624614A (zh) * | 2012-03-28 | 2018-10-09 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv11 l1蛋白的方法 |
JP6423987B2 (ja) | 2012-06-07 | 2018-11-14 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアThe Children’S Hospital Of Philadelphia | 制御された遺伝子発現方法 |
CN103992395B (zh) * | 2013-02-18 | 2018-07-27 | 北京康乐卫士生物技术股份有限公司 | 重组hpv-58型l1的vlp疫苗及其制备方法 |
CN104120088B (zh) * | 2013-04-26 | 2019-09-24 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv58 l1蛋白的方法 |
CN104164374B (zh) * | 2013-05-17 | 2019-10-22 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv31 l1蛋白的方法 |
CN104164373B (zh) * | 2013-05-17 | 2019-04-02 | 北京安百胜生物科技有限公司 | 用汉逊酵母表达系统产生hpv68l1蛋白的方法 |
EP3057612B1 (en) | 2013-10-16 | 2020-05-06 | Merck Sharp & Dohme Corp. | Method of obtaining thermostable dried vaccine formulations |
MA40624A (fr) * | 2014-09-11 | 2016-03-17 | Cadila Healthcare Ltd | Antigènes supérieurs du papillomavirus présentant des propriétés immunologiques supérieures et vaccin les contenant |
CN117187263A (zh) * | 2015-03-30 | 2023-12-08 | 上海泽润生物科技有限公司 | 重组人乳头瘤病毒33亚型蛋白表达 |
CN104878022A (zh) * | 2015-04-27 | 2015-09-02 | 段青姣 | 编码hpv58l1、hpv52l1蛋白的核苷酸序列及其应用 |
US10940194B2 (en) * | 2015-12-04 | 2021-03-09 | Xiamen University | Mutant of L1 protein of human papillomavirus type 58 |
WO2021163002A1 (en) | 2020-02-14 | 2021-08-19 | Merck Sharp & Dohme Corp. | Hpv vaccine |
CN113073105B (zh) * | 2021-03-23 | 2023-06-13 | 重庆博唯佰泰生物制药有限公司 | 一种表达hpv 56l1的多核苷酸序列及其表达载体、宿主细胞和应用 |
CN113549634B (zh) * | 2021-06-07 | 2023-03-31 | 郑州大学 | 编码可溶性hpv58 l1蛋白的基因及其重组质粒的构建与应用 |
US20230048144A1 (en) | 2021-08-06 | 2023-02-16 | Merck Sharp & Dohme Llc | Hpv vaccine |
WO2023023152A1 (en) | 2021-08-19 | 2023-02-23 | Merck Sharp & Dohme Llc | Thermostable lipid nanoparticle and methods of use thereof |
CN117054647A (zh) * | 2023-07-17 | 2023-11-14 | 广东省一鼎生物技术有限公司 | 一种检测HPV IgG抗体试剂盒及其制备方法 |
Family Cites Families (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL117591A0 (en) * | 1995-03-30 | 1996-07-23 | Merck & Co Inc | Synthetic DNA encoding human papillomavirus type 11 L1 protein |
US5821087A (en) * | 1995-03-30 | 1998-10-13 | Merck & Co., Inc. | Production of recombinant human papillomavirus type II protein utilizing papillomavirus 6/11 hybrid DNA |
ES2274566T3 (es) | 1997-02-07 | 2007-05-16 | MERCK & CO., INC. | Genes gag del vih sinteticos. |
WO1999002694A1 (en) | 1997-07-09 | 1999-01-21 | The University Of Queensland | Nucleic acid sequence and method for selectively expressing a protein in a target cell or tissue |
JP4563582B2 (ja) | 1998-08-14 | 2010-10-13 | メルク・シャープ・エンド・ドーム・コーポレイション | ヒトパピローマウイルスのウイルス様粒子を使用するタンパク質送達系 |
CN1354787A (zh) * | 1998-08-14 | 2002-06-19 | 麦克公司 | 纯化人乳头瘤病毒样颗粒的方法 |
SE514982C2 (sv) * | 1999-09-30 | 2001-05-28 | Active Biotech Ab | Bärare innehållande ett huvudkapsidprotein L1 från humant papillomavirus samt dess användning |
CA2381991A1 (en) | 1999-08-25 | 2001-03-01 | Merck & Co., Inc. | Synthetic human papillomavirus genes |
US6436402B1 (en) | 1999-10-15 | 2002-08-20 | Merck & Co., Inc. | Process for making human papillomavirus virus-like particles with improved properties |
US7026443B1 (en) * | 1999-12-10 | 2006-04-11 | Epimmune Inc. | Inducing cellular immune responses to human Papillomavirus using peptide and nucleic acid compositions |
CN1262665C (zh) | 2000-07-21 | 2006-07-05 | 葛兰素集团有限公司 | 经过密码子最优化的乳头状瘤病毒序列 |
AU2003213065A1 (en) * | 2002-02-14 | 2003-09-04 | Novavax, Inc. | Novel insect cell line |
MXPA05010285A (es) | 2003-03-24 | 2005-11-17 | Merck & Co Inc | Expresion optimizada de hpv 31 l1 en levadura. |
MY140664A (en) | 2003-09-29 | 2010-01-15 | Merck Sharp & Dohme | Optimized expression of hpv 45 l1 in yeast |
-
2004
- 2004-11-09 MY MYPI20044678A patent/MY139500A/en unknown
- 2004-11-10 AR ARP040104141A patent/AR046835A1/es active IP Right Grant
- 2004-11-10 EP EP04810619A patent/EP1687329B8/en active Active
- 2004-11-10 DK DK04810619.9T patent/DK1687329T3/da active
- 2004-11-10 US US10/579,111 patent/US7498036B2/en active Active
- 2004-11-10 DE DE602004024821T patent/DE602004024821D1/de active Active
- 2004-11-10 AT AT04810619T patent/ATE452977T1/de active
- 2004-11-10 CN CN2004800332355A patent/CN1942583B/zh active Active
- 2004-11-10 ES ES04810619T patent/ES2340287T3/es active Active
- 2004-11-10 NZ NZ546697A patent/NZ546697A/en unknown
- 2004-11-10 RU RU2006120402/13A patent/RU2370538C2/ru active
- 2004-11-10 WO PCT/US2004/037372 patent/WO2005047315A2/en active Application Filing
- 2004-11-10 PL PL04810619T patent/PL1687329T3/pl unknown
- 2004-11-10 BR BRPI0416393-1A patent/BRPI0416393B1/pt active IP Right Grant
- 2004-11-10 CA CA2543928A patent/CA2543928C/en active Active
- 2004-11-10 JP JP2006539751A patent/JP4912885B2/ja active Active
- 2004-11-10 KR KR1020067009199A patent/KR101170654B1/ko active Protection Beyond IP Right Term
- 2004-11-10 AU AU2004290032A patent/AU2004290032B2/en active Active
- 2004-11-10 PT PT04810619T patent/PT1687329E/pt unknown
- 2004-11-10 SI SI200431328T patent/SI1687329T1/sl unknown
- 2004-11-11 TW TW093134524A patent/TWI332988B/zh active
-
2006
- 2006-04-19 ZA ZA200603106A patent/ZA200603106B/en unknown
- 2006-04-21 IS IS8425A patent/IS2741B/is unknown
- 2006-05-01 IL IL175353A patent/IL175353A/en active IP Right Grant
- 2006-06-09 NO NO20062674A patent/NO340633B1/no active Protection Beyond IP Right Term
-
2009
- 2009-01-26 US US12/321,797 patent/US7976848B2/en active Active
-
2010
- 2010-03-19 CY CY20101100258T patent/CY1113875T1/el unknown
-
2011
- 2011-12-08 JP JP2011268598A patent/JP5616879B2/ja active Active
-
2015
- 2015-11-30 NL NL300775C patent/NL300775I2/nl unknown
- 2015-12-02 HU HUS1500064C patent/HUS1500064I1/hu unknown
- 2015-12-04 FR FR15C0081C patent/FR15C0081I2/fr active Active
- 2015-12-07 CY CY2015051C patent/CY2015051I1/el unknown
- 2015-12-08 LT LTPA2015048C patent/LTC1687329I2/lt unknown
- 2015-12-08 LU LU92901C patent/LU92901I2/xx unknown
- 2015-12-09 BE BE2015C070C patent/BE2015C070I2/nl unknown
-
2017
- 2017-11-10 NO NO2017058C patent/NO2017058I1/no unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NO20062674L (no) | Optimalisert uttrykking av HPV58-L1 i gjaer | |
NO20061876L (no) | Optimalisert uttrykking av HPV45-L1 i gjaer | |
NO20064815L (no) | Optimalisert uttrykking av HPV 52-L1 i gjaer | |
NO2018010I1 (no) | HPV 31 L1 protein | |
ATE489969T1 (de) | Verpackte virusartige partikel in kombination mit cpg zur verwendung als adjuvantien mit allergenen. herstellungsverfahren und verwendung | |
DE60234375D1 (de) | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG | |
ES2422580T3 (es) | Partículas funcionales similares al virus (VLP) de la gripe | |
WO2004084939A3 (en) | Hiv-peptide-carrier-conjugates | |
ATE386105T1 (de) | Chimäre humane papillomavirus (hpv) l1 moleküle und deren verwendungen | |
NZ589755A (en) | Vaccine composition useful for hpv and hepatitis b infections and a method for preparing the same | |
NZ516725A (en) | Use of modified HPV as a carrier for vaccine against cancer or viral infection of human papillomavirus | |
TW200607858A (en) | Optimized expression of HPV 31 L1 in yeast | |
TH108752B (th) | การแสดงที่ถูกทำให้เหมาะสมที่สุดของ hpv 52 l1 ในยีสต์ | |
MY138895A (en) | Optimized expression of hpv 31 l1 in yeast |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: HPV 58 L1 PROTEIN; NAT. REG. NO/DATE: EU/1/15/1007/001-3NO 20150618; FIRST REG. NO/DATE: EU/1/15/1007/1001-3 20150612 Spc suppl protection certif: 2017058 Filing date: 20171110 |
|
SPCG | Granted supplementary protection certificate |
Free format text: PRODUCT NAME: HPV 58 L1 PROTEIN; NAT. REG. NO/DATE: EU/1/15/1007/001-3NO 20150618; FIRST REG. NO/DATE: EU/1/15/1007/1001-3 20150612 Spc suppl protection certif: 2017058 Filing date: 20171110 Extension date: 20291110 |
|
CHAD | Change of the owner's name or address (par. 44 patent law, par. patentforskriften) |
Owner name: MERCK SHARP & DOHME LLC, US |
|
SPCF | Filing of supplementary protection certificate |
Free format text: PRODUCT NAME: HPV 58L1 PROTEIN - FORLENGET SPC; REG. NO/DATE: EU/1/15/1007/001-3NO 20150618 Spc suppl protection certif: 2022052 Filing date: 20221130 |